Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Gynecol Oncol ; 101(2): 363-6, 2006 May.
Article in English | MEDLINE | ID: mdl-16439005

ABSTRACT

BACKGROUND: Extragastrointestinal stromal tumors (eGISTs) are rare mesenchymal-derived tumors arising outside of the GI tract. eGISTs are often histologically confused with leiomyosarcoma. Distinction between eGIST and leiomyosarcoma is critical because of the unique responsiveness of eGISTs to the molecularly targeted agent imatinib. CASE: A woman presented with a history of tubal spindle cell tumor that was initially diagnosed and treated as a leiomyosarcoma. Because of minimal response to sarcoma directed chemotherapy, the possibility that the tumor was in fact an eGIST was investigated and supported by immunohistochemical and mutational analyses of the c-Kit receptor tyrosine kinase. The patient currently has stable disease control on imatinib for the last 18 months. CONCLUSIONS: The possibility of eGIST should be considered in the differential diagnosis of tumors with a spindle cell morphology in the gynecologic tract especially when involving the ovary, fallopian tube, or uterine serosa.


Subject(s)
Fallopian Tube Neoplasms/genetics , Gastrointestinal Stromal Tumors/genetics , Leiomyosarcoma/genetics , Proto-Oncogene Proteins c-kit/genetics , Base Sequence , Diagnosis, Differential , Fallopian Tube Neoplasms/diagnosis , Fallopian Tube Neoplasms/enzymology , Female , Gastrointestinal Stromal Tumors/diagnosis , Humans , Leiomyosarcoma/diagnosis , Leiomyosarcoma/enzymology , Middle Aged , Molecular Sequence Data
2.
Psychopharmacology (Berl) ; 180(3): 447-54, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15700179

ABSTRACT

RATIONALE: Allopregnanolone, a neurosteroid-reduced metabolite of progesterone, is a well-documented positive modulator of the gamma-aminobutyric type A (GABA(A)) receptor. As has been reported for other positive modulators of the GABA(A) receptor, chronic exposure to neurosteroids is hypothesized to decrease GABA(A) receptor function. Drawing from the literature on chronic exposure to benzodiazepines or alcohol, putative changes in N-methyl-D-aspartate (NMDA) receptor function are also expected after chronic neurosteroid exposure. OBJECTIVES: To assess the sensitivity of the GABA(A) and NMDA receptors after chronic elevation of neurosteroid produced by termination of pseudopregnancy in behavioral tests of anxiety and sensorimotor coordination. METHODS: Female rats ovariectomized on day 10 of pseudopregnancy were tested in the elevated plus-maze and on the rotor rod after an acute injection of progesterone (4 mg/0.2 ml, s.c.), chlordiazepoxide (5 or 15 mg/kg, i.p.), or MK-801 (0.025, 0.05, or 0.1 mg/kg, i.p.). RESULTS: Pseudopregnancy termination produced an anxiogenic-like response in the plus-maze; an acute injection of progesterone restored baseline levels of behavior in this test. Pseudopregnancy termination eliminated the anxiolytic-like, sedative, and ataxic effects of chlordiazepoxide. In contrast, pseudopregnancy termination produced an increased sensitivity to the anxiolytic-like and ataxic effects of MK-801. CONCLUSIONS: The effects of pseudopregnancy termination on the behavioral response to positive modulators of the GABA(A) receptor are consistent with results from studies in which chronic exposure to neurosteroids decreases the response to acute neurosteroid and benzodiazepine administration. However, unlike the enhanced glutamatergic tone resulting from discontinuation of chronic benzodiazepine or alcohol exposure, the termination of pseudopregnancy apparently decreases NMDA receptor function.


Subject(s)
Chlordiazepoxide/pharmacology , Dizocilpine Maleate/pharmacology , Maze Learning/drug effects , Progesterone/pharmacology , Pseudopregnancy/physiopathology , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/pharmacology , Chlordiazepoxide/administration & dosage , Dizocilpine Maleate/administration & dosage , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/pharmacology , Exploratory Behavior/drug effects , Female , Gonadotropins, Equine/administration & dosage , Motor Activity/drug effects , Ovariectomy , Pregnanolone/administration & dosage , Progesterone/administration & dosage , Pseudopregnancy/chemically induced , Random Allocation , Rats , Rats, Long-Evans
3.
Brain Res Mol Brain Res ; 102(1-2): 118-28, 2002 Jun 15.
Article in English | MEDLINE | ID: mdl-12191502

ABSTRACT

The diminished expression of D1 and D2 dopamine receptors is a well-documented hallmark of Huntington's disease (HD), but relatively little is known about how these changes in receptor populations affect the dopaminergic responses of striatal neurons. Using transgenic mice expressing an N-terminal portion of mutant huntingtin (R6/2 mice), we have examined immediate early gene (IEG) expression as an index of dopaminergic signal transduction. c-fos, jun B, zif268, and N10 mRNA levels and expression patterns were analyzed using quantitative in situ hybridization histochemistry following intraperitoneal administration of selective D1 and D2 family pharmacological agents (SKF-82958 and eticlopride). Basal IEG levels were generally lower in the dorsal subregion of R6/2 striata relative to wild-type control striata at 10-11 weeks of age, a finding in accord with previously reported decreases in D1 and adenosine A2A receptors. D2-antagonist-stimulated IEG expression was significantly reduced in the striata of transgenic animals. In contrast, D1-agonist-induced striatal R6/2 IEG mRNA levels were either equivalent or significantly enhanced relative to control levels, an unexpected result given the reduced level of D1 receptors in R6/2 animals. Understanding the functional bases for these effects may further elucidate the complex pathophysiology of Huntington's disease.


Subject(s)
Gene Expression Regulation/genetics , Genes, Immediate-Early/genetics , Huntington Disease/genetics , Neostriatum/metabolism , Neurons/metabolism , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Animals , Disease Models, Animal , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Female , Gene Expression Regulation/drug effects , Genes, Immediate-Early/drug effects , Huntingtin Protein , Huntington Disease/metabolism , Huntington Disease/physiopathology , Male , Mice , Mice, Transgenic , Neostriatum/drug effects , Neostriatum/physiopathology , Nerve Tissue Proteins/deficiency , Nerve Tissue Proteins/genetics , Neurons/drug effects , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , RNA, Messenger/metabolism , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D1/genetics , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/genetics , Transcriptional Activation
4.
Hum Mol Genet ; 11(17): 1939-51, 2002 Aug 15.
Article in English | MEDLINE | ID: mdl-12165556

ABSTRACT

Both transcriptional dysregulation and proteolysis of mutant huntingtin (htt) are postulated to be important components of Huntington's disease (HD) pathogenesis. In previous studies, we demonstrated that transgenic mice that express short mutant htt fragments containing 171 or fewer N-terminal residues (R6/2 and N171-82Q mice) recapitulate many of the mRNA changes observed in human HD brain. To examine whether htt protein length influences the ability of its expanded polyglutamine domain to alter gene expression, we conducted mRNA profiling analyses of mice that express an extended N-terminal fragment (HD46, HD100; 964 amino acids) or full-length (YAC72; 3144 amino acids) mutant htt transprotein. Oligonucleotide microarray analyses of HD46 and YAC72 mice identified fewer differentially expressed mRNAs than were seen in transgenic mice expressing short N-terminal mutant htt fragments. Histologic analyses also detected limited changes in these mice (small decreases in adenosine A2a receptor mRNA and dopamine D2 receptor binding in HD100 animals; small increases in dopamine D1 receptor binding in HD46 and HD100 mice). Neither HD46 nor YAC72 mice exhibited altered mRNA levels similar to those observed previously in R6/2 mice, N171-82Q mice or human HD patients. These findings suggest that htt protein length influences the ability of an expanded polyglutamine domain to alter gene expression. Furthermore, our findings suggest that short N-terminal fragments of mutant htt might be responsible for the gene expression alterations observed in human HD brain.


Subject(s)
Brain/metabolism , Huntington Disease/genetics , Peptides/genetics , Proteins/genetics , Animals , Blotting, Northern , Brain/pathology , Disease Models, Animal , Female , Gene Expression Profiling , Humans , Huntingtin Protein , Huntington Disease/metabolism , Huntington Disease/pathology , In Situ Hybridization , Male , Mice , Mice, Transgenic , Molecular Sequence Data , Nerve Tissue Proteins , Nuclear Proteins , Oligonucleotide Array Sequence Analysis , RNA, Messenger/metabolism , Receptor, Adenosine A2A , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/metabolism , Receptors, Purinergic P1/genetics , Receptors, Purinergic P1/metabolism , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...